Sabrina McCrear

Learn what sickle cell disease is, who it affects most, today’s treatment options, and how cost and inequities limit access.

A systematic review finds that diagnostic discordance in bone and soft tissue sarcoma may reduce survival, supporting expert second opinions.

Advances in sickle cell therapies, including gene editing, offer hope—but racial disparities, cost, and access barriers remain major challenges.

A new study links telomere length and polygenic risk scores to IPF development, highlighting genetic drivers beyond rare variants.

A new study links telomere length genetics to IPF risk, showing how rare variants and polygenic scores may guide future screening and precision care.

Sarah M. Lima, PhD, MPH, on how historical redlining continues to shape breast cancer survival disparities through treatment access and innovation.

Ricciuti explains why advanced adoptive cell therapies require major infrastructure, toxicity management, and strong academic–community collaboration.

Study finds breast cancer survival gaps tied to historical redlining narrowed over time, though newer therapies may be widening disparities again.

Biagio Ricciuti, MD, discusses how access challenges and toxicity concerns slow the rollout of new T-cell engager therapies from academic centers into community oncology.

Anasuya Gunturi, MD, PhD, explains how academic–community partnerships help deliver complex oncology services closer to home.

Andrew Yee, MD, explains how academic centers can share practical oncology best practices that community hospitals can implement sustainably.

Community-academic collaboration can reduce access burdens and strengthen continuity of care, says Anasuya Gunturi, MD, PhD.

A Commonwealth Fund analysis finds employer health premiums and deductibles exceed 10% of income in 19 states, worsening affordability gaps.

A survey found many patients with long-term conditions prefer remote visits for results and refills, but some trade continuity for faster care.

Osama Abdelghany, PharmD, explains how medically integrated dispensing improves oncology workflows, patient access, and outcomes through EMR-driven care.

Community partnerships and trial design reforms can reduce travel barriers and improve underserved patient representation, said Amir Fathi, MD.

Catchment areas, access, and partnerships influence diversity in oncology trials, Amir Fathi, MD, explains at a Boston IVBM panel.

Medically integrated dispensing improves oncology treatment coordination through EMR-based care, but payer restrictions remain a key barrier.

City St. George’s researchers identified 9 genetic signatures and epigenetic changes driving lapatinib resistance in HER2-positive breast cancer.

Ateequllah Hayat, PhD, discusses epigenetic rewiring, biomarkers, and emerging strategies to overcome lapatinib resistance in HER2+ breast cancer.

A spending bill advancing PBM reforms aims to delink Medicare Part D compensation from drug rebates and improve pricing transparency.

Telomere length and polygenic risk independently influence IPF susceptibility, even among patients without rare genetic variants.

A European Respiratory Journal study shows pulmonary fibrosis affects sexual function and quality of life, calling for open clinician-patient conversations.

AAP’s 2026 immunization schedule continues protection against 18 diseases as the CDC reduces its recommendations to 11.

Minnesota physicians warn ICE activity in hospitals and clinics is deterring care, undermining patient safety, and worsening health outcomes.

CMS’s 2027 proposed MA payment rate increase of .09% falls short of expectations, potentially increasing premiums and reducing benefits for seniors.

ACE inhibitors may improve survival in IPF patients, highlighting potential repurposing of a common cardiovascular drug.

Phase 2 trial results show anlotinib with anthracyclines and ifosfamide yields a 30.8% ORR and an 82.7% DCR in advanced soft tissue sarcoma.

A multistakeholder study explores how law enforcement presence in EDs affects survivors of violence and outlines trauma-informed, patient-centered policy solutions.

Socioeconomic and demographic factors influenced amputation and recurrence rates in upper extremity soft tissue sarcoma.